Pfizer biotech spinout nabs $125M megaround as Bain-backed syndicate bets on its late-stage game plan
SpringWorks Therapeutics launched in the fall of 2017 with a whopping $103 million round and some well-developed Pfizer assets that the company had high hopes for. And now Bain, Pfizer and the rest of the founding investors have joined hands with an even bigger group of investors led by Perceptive to bankroll a pair of late-stage studies ready to begin in a matter of weeks.
The Series B weighs in at a heavyweight $125 million, bringing their total raise to $228 million, with access to more if needed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
